Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Blood neurofilament light levels segregate treatment effects in multiple sclerosis.

Delcoigne B, Manouchehrinia A, Barro C, Benkert P, Michalak Z, Kappos L, Leppert D, Tsai JA, Plavina T, Kieseier BC, Lycke J, Alfredsson L, Kockum I, Kuhle J, Olsson T, Piehl F.

Neurology. 2020 Feb 11. pii: 10.1212/WNL.0000000000009097. doi: 10.1212/WNL.0000000000009097. [Epub ahead of print]

PMID:
32047070
2.

Serum neurofilament light levels in normal aging and their association with morphologic brain changes.

Khalil M, Pirpamer L, Hofer E, Voortman MM, Barro C, Leppert D, Benkert P, Ropele S, Enzinger C, Fazekas F, Schmidt R, Kuhle J.

Nat Commun. 2020 Feb 10;11(1):812. doi: 10.1038/s41467-020-14612-6.

3.

Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy.

Maia LF, Maceski A, Conceição I, Obici L, Magalhães R, Cortese A, Leppert D, Merlini G, Kuhle J, Saraiva MJ.

Amyloid. 2020 Jan 6:1-6. doi: 10.1080/13506129.2019.1708716. [Epub ahead of print]

PMID:
31906707
4.

A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.

Tavazzi E, Bergsland N, Kuhle J, Jakimovski D, Ramanathan M, Maceski AM, Tomic D, Hagemeier J, Kropshofer H, Leppert D, Dwyer MG, Weinstock-Guttman B, Benedict RHB, Zivadinov R.

J Neurol. 2019 Nov 25. doi: 10.1007/s00415-019-09643-z. [Epub ahead of print]

PMID:
31768628
5.

Serum NfL levels should be used to monitor multiple sclerosis evolution - Yes.

Leppert D, Kuhle J.

Mult Scler. 2020 Jan;26(1):17-19. doi: 10.1177/1352458519872921. Epub 2019 Oct 18. No abstract available.

PMID:
31625807
6.

Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.

Jakimovski D, Zivadinov R, Ramanthan M, Hagemeier J, Weinstock-Guttman B, Tomic D, Kropshofer H, Fuchs TA, Barro C, Leppert D, Yaldizli Ö, Kuhle J, Benedict RH.

Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428. [Epub ahead of print]

PMID:
31610732
7.

Blood neurofilament light chain at the doorstep of clinical application.

Leppert D, Kuhle J.

Neurol Neuroimmunol Neuroinflamm. 2019 Aug 8;6(5):e599. doi: 10.1212/NXI.0000000000000599. eCollection 2019 Sep. No abstract available.

8.

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.

Watanabe M, Nakamura Y, Michalak Z, Isobe N, Barro C, Leppert D, Matsushita T, Hayashi F, Yamasaki R, Kuhle J, Kira JI.

Neurology. 2019 Sep 24;93(13):e1299-e1311. doi: 10.1212/WNL.0000000000008160. Epub 2019 Aug 30.

PMID:
31471502
9.

Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.

Jakimovski D, Kuhle J, Ramanathan M, Barro C, Tomic D, Hagemeier J, Kropshofer H, Bergsland N, Leppert D, Dwyer MG, Michalak Z, Benedict RHB, Weinstock-Guttman B, Zivadinov R.

Ann Clin Transl Neurol. 2019 Sep;6(9):1757-1770. doi: 10.1002/acn3.50872. Epub 2019 Aug 22. Erratum in: Ann Clin Transl Neurol. 2019 Dec;6(12):2607.

10.

Low-Dose Subcutaneous Anti-CD20 Treatment Depletes Disease Relevant B Cell Subsets and Attenuates Neuroinflammation.

Huck C, Leppert D, Wegert V, Schmid C, Dunn R, Weckbecker G, Smith PA.

J Neuroimmune Pharmacol. 2019 Dec;14(4):709-719. doi: 10.1007/s11481-019-09872-z. Epub 2019 Aug 21.

PMID:
31435856
11.

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years.

Cantó E, Barro C, Zhao C, Caillier SJ, Michalak Z, Bove R, Tomic D, Santaniello A, Häring DA, Hollenbach J, Henry RG, Cree BAC, Kappos L, Leppert D, Hauser SL, Benkert P, Oksenberg JR, Kuhle J.

JAMA Neurol. 2019 Aug 12. doi: 10.1001/jamaneurol.2019.2137. [Epub ahead of print]

PMID:
31403661
12.

Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys.

Theil D, Smith P, Huck C, Gilbart Y, Kakarieka A, Leppert D, Rauld C, Schmid C, Baumgartner R, Stuber N, Cordoba F, Dubost V, Darribat K, Jivkov M, Frieauff W, Kneuer R, Stoeckli M, Reinker S, Mansfield K, Carballido JM, Couttet P, Weckbecker G.

Front Immunol. 2019 Jun 20;10:1340. doi: 10.3389/fimmu.2019.01340. eCollection 2019.

13.

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS.

Sormani MP, Haering DA, Kropshofer H, Leppert D, Kundu U, Barro C, Kappos L, Tomic D, Kuhle J.

Ann Clin Transl Neurol. 2019 May 28;6(6):1081-1089. doi: 10.1002/acn3.795. eCollection 2019 Jun.

14.

MMPs and ADAMs in neurological infectious diseases and multiple sclerosis.

Muri L, Leppert D, Grandgirard D, Leib SL.

Cell Mol Life Sci. 2019 Aug;76(16):3097-3116. doi: 10.1007/s00018-019-03174-6. Epub 2019 Jun 6. Review.

PMID:
31172218
15.

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.

Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, Dahlke F, Tomic D, Leppert D, Kappos L.

Neurology. 2019 Mar 5;92(10):e1007-e1015. doi: 10.1212/WNL.0000000000007032. Epub 2019 Feb 8.

16.

Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.

Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, Häring D, Leppert D, Kappos L, Bakshi R, Weiner HL, Kuhle J.

Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. doi: 10.1002/acn3.638. eCollection 2018 Dec.

17.

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.

Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera C, Yaldizli Ö, Michalak Z, Wuerfel J, Kappos L, Parmar K, Kuhle J.

Brain. 2018 Aug 1;141(8):2382-2391. doi: 10.1093/brain/awy154.

PMID:
29860296
18.

MIBG scintigraphy of the major salivary glands in multiple system atrophy.

Soboll L, Leppert D, Dillmann U, Schaefer-Schuler A, Fassbender K, Ezziddin S, Spiegel J.

Parkinsonism Relat Disord. 2018 Aug;53:112-114. doi: 10.1016/j.parkreldis.2018.04.034. Epub 2018 May 4.

PMID:
29752191
19.

Fluid biomarker and electrophysiological outcome measures for progressive MS trials.

Barro C, Leocani L, Leppert D, Comi G, Kappos L, Kuhle J.

Mult Scler. 2017 Oct;23(12):1600-1613. doi: 10.1177/1352458517732844. Review.

PMID:
29041870
20.

'Progressive MS - macro views': The need for novel clinical trial paradigms to enable drug development for progressive MS.

Zaratin P, Comi G, Leppert D.

Mult Scler. 2017 Oct;23(12):1649-1655. doi: 10.1177/1352458517729457. Review.

PMID:
29041866
21.

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.

Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J; Swiss Multiple Sclerosis Cohort Study Group.

Ann Neurol. 2017 Jun;81(6):857-870. doi: 10.1002/ana.24954.

22.

Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.

Giovannoni G, Cutter G, Sormani MP, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D, Leppert D, Herndon R, Wheeler-Kingshott CAM, Ciccarelli O, Selwood D, di Cantogno EV, Ben-Amor AF, Matthews P, Carassiti D, Baker D, Schmierer K.

Mult Scler Relat Disord. 2017 Feb;12:70-78. doi: 10.1016/j.msard.2017.01.007. Epub 2017 Jan 17. Review.

PMID:
28283111
23.

Bilateral Endoscopic Lung Volume Reduction in Patients with Severe Emphysema.

Trudzinski FC, Lepper PM, Leppert D, Langer F, Lensch C, Flaig M, Bals R, Wilkens H, Minko P, Fähndrich S.

Respiration. 2016;92(5):356-358. Epub 2016 Oct 5.

24.

Reduced MIBG accumulation of the parotid and submandibular glands in idiopathic Parkinson's disease.

Haqparwar J, Pepe A, Fassbender K, Dillmann U, Ezziddin S, Schaefer A, Leppert D, Spiegel J.

Parkinsonism Relat Disord. 2017 Jan;34:26-30. doi: 10.1016/j.parkreldis.2016.10.011. Epub 2016 Oct 15.

PMID:
27769648
25.

Endoscopic Lung Volume Reduction Using Endobronchial Valves in Patients with Severe Emphysema and Very Low FEV1.

Trudzinski FC, Höink AJ, Leppert D, Fähndrich S, Wilkens H, Graeter TP, Langer F, Bals R, Minko P, Lepper PM.

Respiration. 2016;92(4):258-265. Epub 2016 Sep 8.

26.

The effects of intrathecal rituximab on biomarkers in multiple sclerosis.

Topping J, Dobson R, Lapin S, Maslyanskiy A, Kropshofer H, Leppert D, Giovannoni G, Evdoshenko E.

Mult Scler Relat Disord. 2016 Mar;6:49-53. doi: 10.1016/j.msard.2016.01.001. Epub 2016 Jan 19.

PMID:
27063622
27.

The matrix metalloproteinase inhibitor RS-130830 attenuates brain injury in experimental pneumococcal meningitis.

Liechti FD, Bächtold F, Grandgirard D, Leppert D, Leib SL.

J Neuroinflammation. 2015 Mar 4;12:43. doi: 10.1186/s12974-015-0257-0.

28.

(11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas.

Park E, Gallezot JD, Delgadillo A, Liu S, Planeta B, Lin SF, O'Connor KC, Lim K, Lee JY, Chastre A, Chen MK, Seneca N, Leppert D, Huang Y, Carson RE, Pelletier D.

Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1081-92. doi: 10.1007/s00259-015-3043-4. Epub 2015 Apr 2.

PMID:
25833352
29.

Anti-CD20 inhibits T cell-mediated pathology and microgliosis in the rat brain.

Anthony DC, Dickens AM, Seneca N, Couch Y, Campbell S, Checa B, Kersemans V, Warren EA, Tredwell M, Sibson NR, Gouverneur V, Leppert D.

Ann Clin Transl Neurol. 2014 Sep;1(9):659-69. doi: 10.1002/acn3.94. Epub 2014 Sep 16.

30.

Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome.

Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A, Lu CH, Dobson R, Disanto G, Norgren N, Nissim A, Kappos L, Hurlbert J, Yong VW, Giovannoni G, Casha S.

J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):273-9. doi: 10.1136/jnnp-2013-307454. Epub 2014 Jun 16.

PMID:
24935984
31.

Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.

Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, Baranzini SE, Leppert D, von Büdingen HC.

J Immunol. 2014 Jul 15;193(2):580-586. doi: 10.4049/jimmunol.1400118. Epub 2014 Jun 13.

32.

Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.

Villar LM, Casanova B, Ouamara N, Comabella M, Jalili F, Leppert D, de Andrés C, Izquierdo G, Arroyo R, Avşar T, Lapin SV, Johnson T, Montalbán X, Fernández O, Álvarez-Lafuente R, Masterman D, García-Sánchez MI, Coret F, Siva A, Evdoshenko E, Álvarez-Cermeño JC, Bar-Or A.

Ann Neurol. 2014 Aug;76(2):231-40. doi: 10.1002/ana.24190. Epub 2014 Jul 2.

PMID:
24909126
33.

Composite end points to assess delay of disability progression by MS treatments.

Zhang J, Waubant E, Cutter G, Wolinsky J, Leppert D.

Mult Scler. 2014 Oct;20(11):1494-501. doi: 10.1177/1352458514527180. Epub 2014 Mar 27.

PMID:
24675040
34.

Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis.

Liechti FD, Grandgirard D, Leppert D, Leib SL.

Infect Immun. 2014 Apr;82(4):1710-8. doi: 10.1128/IAI.00073-14. Epub 2014 Feb 3. Erratum in: Infect Immun. 2014 Oct;82(10):4435.

35.

Glial activation in the early stages of brain metastasis: TSPO as a diagnostic biomarker.

O'Brien ER, Kersemans V, Tredwell M, Checa B, Serres S, Soto MS, Gouverneur V, Leppert D, Anthony DC, Sibson NR.

J Nucl Med. 2014 Feb;55(2):275-80. doi: 10.2967/jnumed.113.127449. Epub 2014 Jan 16.

36.

Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model.

Anthony DC, Sibson NR, Losey P, Meier DP, Leppert D.

Neuropharmacology. 2014 Apr;79:534-41. doi: 10.1016/j.neuropharm.2013.12.022. Epub 2014 Jan 9.

PMID:
24412675
37.

Increased neurofilament light chain blood levels in neurodegenerative neurological diseases.

Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, Bestwick JP, Monsch AU, Regeniter A, Lindberg RL, Kappos L, Leppert D, Petzold A, Giovannoni G, Kuhle J.

PLoS One. 2013 Sep 20;8(9):e75091. doi: 10.1371/journal.pone.0075091. eCollection 2013.

38.

Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.

Gobbi C, Meier DS, Cotton F, Sintzel M, Leppert D, Guttmann CR, Zecca C.

BMC Neurol. 2013 Aug 2;13:101. doi: 10.1186/1471-2377-13-101.

39.

A comparative study of CSF neurofilament light and heavy chain protein in MS.

Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, Norgren N, Nissim A, Malaspina A, Leppert D, Giovannoni G, Kappos L.

Mult Scler. 2013 Oct;19(12):1597-603. doi: 10.1177/1352458513482374. Epub 2013 Mar 25.

PMID:
23529999
40.

On being a neurologist in industry.

Leppert D, Glanzman R.

Ann Neurol. 2013 Mar;73(3):319-26. doi: 10.1002/ana.23812. Epub 2013 Feb 19.

PMID:
23423974
41.

Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

Gensicke H, Leppert D, Yaldizli Ö, Lindberg RL, Mehling M, Kappos L, Kuhle J.

CNS Drugs. 2012 Jan 1;26(1):11-37. doi: 10.2165/11596920-000000000-00000. Review.

PMID:
22171583
42.

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL.

Lancet. 2011 Nov 19;378(9805):1779-87. doi: 10.1016/S0140-6736(11)61649-8. Epub 2011 Oct 31.

PMID:
22047971
43.

Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.

Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, Anthony DC, Kappos L, Lindberg RL.

Neurology. 2011 Apr 5;76(14):1206-13. doi: 10.1212/WNL.0b013e31821432ff. Epub 2011 Feb 23.

PMID:
21346223
44.

Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study.

Kasperaviciūte D, Catarino CB, Heinzen EL, Depondt C, Cavalleri GL, Caboclo LO, Tate SK, Jamnadas-Khoda J, Chinthapalli K, Clayton LM, Shianna KV, Radtke RA, Mikati MA, Gallentine WB, Husain AM, Alhusaini S, Leppert D, Middleton LT, Gibson RA, Johnson MR, Matthews PM, Hosford D, Heuser K, Amos L, Ortega M, Zumsteg D, Wieser HG, Steinhoff BJ, Krämer G, Hansen J, Dorn T, Kantanen AM, Gjerstad L, Peuralinna T, Hernandez DG, Eriksson KJ, Kälviäinen RK, Doherty CP, Wood NW, Pandolfo M, Duncan JS, Sander JW, Delanty N, Goldstein DB, Sisodiya SM.

Brain. 2010 Jul;133(Pt 7):2136-47. doi: 10.1093/brain/awq130. Epub 2010 Jun 3.

45.

Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes.

Heinzen EL, Radtke RA, Urban TJ, Cavalleri GL, Depondt C, Need AC, Walley NM, Nicoletti P, Ge D, Catarino CB, Duncan JS, Kasperaviciūte D, Tate SK, Caboclo LO, Sander JW, Clayton L, Linney KN, Shianna KV, Gumbs CE, Smith J, Cronin KD, Maia JM, Doherty CP, Pandolfo M, Leppert D, Middleton LT, Gibson RA, Johnson MR, Matthews PM, Hosford D, Kälviäinen R, Eriksson K, Kantanen AM, Dorn T, Hansen J, Krämer G, Steinhoff BJ, Wieser HG, Zumsteg D, Ortega M, Wood NW, Huxley-Jones J, Mikati M, Gallentine WB, Husain AM, Buckley PG, Stallings RL, Podgoreanu MV, Delanty N, Sisodiya SM, Goldstein DB.

Am J Hum Genet. 2010 May 14;86(5):707-18. doi: 10.1016/j.ajhg.2010.03.018. Epub 2010 Apr 15.

46.

A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.

Kuhle J, Regeniter A, Leppert D, Mehling M, Kappos L, Lindberg RL, Petzold A.

J Neuroimmunol. 2010 Mar 30;220(1-2):114-9. doi: 10.1016/j.jneuroim.2010.01.004. Epub 2010 Feb 1.

PMID:
20117845
47.

AUY954, a selective S1P(1) modulator, prevents experimental autoimmune neuritis.

Zhang ZY, Zhang Z, Zug C, Nuesslein-Hildesheim B, Leppert D, Schluesener HJ.

J Neuroimmunol. 2009 Nov 30;216(1-2):59-65. doi: 10.1016/j.jneuroim.2009.09.010. Epub 2009 Oct 4.

PMID:
19804913
48.

Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures.

Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, Beheshtian A, Waubant E, Zamvil SS, Leppert D, Qualley P, Lincoln R, Gomez R, Caillier S, George M, Wang J, Nelson SJ, Cree BA, Hauser SL, Pelletier D.

Brain. 2009 Jan;132(Pt 1):250-9. doi: 10.1093/brain/awn301. Epub 2008 Nov 20.

49.

Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta2 involves matrix metalloproteinases and tight junction proteins.

Ishihara H, Kubota H, Lindberg RL, Leppert D, Gloor SM, Errede M, Virgintino D, Fontana A, Yonekawa Y, Frei K.

J Neuropathol Exp Neurol. 2008 May;67(5):435-48. doi: 10.1097/NEN.0b013e31816fd622.

PMID:
18431253
50.

Immunomodulatory effects of etanercept in a model of brain injury act through attenuation of the acute-phase response.

Campbell SJ, Jiang Y, Davis AE, Farrands R, Holbrook J, Leppert D, Anthony DC.

J Neurochem. 2007 Dec;103(6):2245-55. Epub 2007 Sep 18.

Supplemental Content

Loading ...
Support Center